SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (147)1/14/2018 1:17:46 PM
From: scaram(o)uche  Respond to of 294
 
Unfortunately, I can't see the figures with sufficient resolution to learn much about any constraints on Fc engagement. First blush, you'd think that engagement of Fc and blocking of SIRPalpha-CD47 by a single molecule would be optimal?? Any justification for our having been "slammed"?




To: scaram(o)uche who wrote (147)1/16/2018 4:17:06 PM
From: Biomaven  Read Replies (1) | Respond to of 294
 
I actually asked the company about SLAMF7 last May. They responded that they had seen "numerous hematologic tumor targets that have minimal SLAMF7 expression but are robustly phagocytosed in the presence of TTI-621."
So maybe it's an issue only for the mabs or for molecules without an effector function.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News